Pharmaceutical Technology

FEBRUARY 16, 2023

Aqilion and Merck have entered an exclusive licence and strategic research partnership for the discovery, development and commercialisation of the transforming growth factor-β-activated kinase 1 (TAK1) protein-small molecule inhibitors. Aqilion will handle the design and synthesis of the new small molecule TAK1 inhibitors.

Protein 147

Protein Development Sales Business Development 147

Pharmaceutical Technology

AUGUST 29, 2024

The Putative Fidgetin Like Protein 2 pipeline drugs market research report outlays comprehensive information on the Putative Fidgetin Like Protein…

Protein 130

Protein Drugs Development Marketing 130

Pharmaceutical Technology

JUNE 15, 2023

Japan-based Astellas Pharma has entered a partnership with Cullgen to discover and develop multiple targeted protein degraders through the latter’s proprietary uSMITE targeted protein degradation platform, in a deal potentially worth $1.9bn. This method can target enzymes, transcription factors, scaffold proteins and more.

Protein 130

Protein Development Licensing Licensing 130

Bio Pharma Dive

MARCH 30, 2021

Two drugs developed by Wave Life Sciences didn't appear to have an effect on disease-causing proteins, another setback for Huntington's research after disappointing results last week from Roche and Ionis.

Life Science 313

Life Science Drugs Protein Trials 313

Pharmaceutical Technology

DECEMBER 16, 2022

Previously disrupted by the Covid-19 pandemic, this past year has seen a return of increased efforts and progress in the development of new treatments for tropical diseases. Both vaccines are based on recombinant proteins and attack the parasite during the sporozoite stage. Research picking up pace for neglected diseases.

Development 264

Development Drugs Vaccination Vaccine 264

Pharmaceutical Technology

MARCH 17, 2023

The Lung Cancer Research Foundation (LCRF) has announced a new research partnership with Daiichi Sankyo and AstraZeneca. This collaboration is intended to fund up to three research grants that are focused on antibody-drug conjugates (ADCs) for improving the outcomes for lung cancer patients.

Research 246

Research Antibody Protein Trials 246

pharmaphorum

AUGUST 5, 2021

Protein-protein interactions (PPIs) are becoming increasingly relevant in the pathology of many diseases, including cancer. The issue, however, is developing an effective way of targeting them. . PPIs are an integral part of the physiology of living organisms, as complexes which control biological pathways mediated by proteins.

Protein 126

Protein Gene Bioassay DNA 126

Pharmaceutical Technology

DECEMBER 5, 2022

Sanofi has signed an agreement with the Queensland Government in Australia to establish a $190m (A$280m) research facility in Brisbane. The hub will connect Queensland scientists with the teams at Sanofi’s mRNA Centre of Excellence in the US and France, putting them at the front of international vaccine development and biomedical research.

Research 246

Research Gene Therapy Vaccination Vaccine 246

Bio Pharma Dive

SEPTEMBER 20, 2023

Targeted protein degradation has emerged as one of the more competitive areas of pharmaceutical research in recent years as scientists develop new ways to reach difficult-to-drug targets.

Drugs 274

Drugs Protein Scientist Development 274

Pharma Times

APRIL 29, 2024

The new process makes generating active pharmaceutical ingredients quicker and easier

Protein 139

Protein Development Research Drugs 139

Pharmaceutical Technology

APRIL 6, 2023

Biotheryx and Incyte have signed an agreement for identifying and developing targeted protein degraders for historically undruggable oncology targets. Further development and commercialisation of any molecular glue degraders will be handled by Incyte alone. These degraders will be identified by the PRODEGY platform.

Protein 130

Protein Development Sales Production 130

Pharmaceutical Technology

FEBRUARY 13, 2023

While several therapeutics are available for treating symptoms associated with epilepsy, researchers and patients have strongly called out the need for more holistic treatments that would address the condition as a whole. Meanwhile, others are researching the link between gene variation and different responses to treatments.

Research 264

Research Gene Gene Therapy Genomics 264

Pharmaceutical Technology

AUGUST 5, 2022

The development of therapeutics for transmissible spongiform encephalopathies (TSEs) continues to be challenged by the complex nature of these diseases. As per the prevailing prion theory, a misfolded version of a normal cell-surface protein acts as the chief infectious agent.

Drugs 299

Drugs Protein Vaccine Vaccination 299

Pharma Times

JULY 26, 2024

Researchers predicted the onset of 67 diseases, out-performing current standard models

Protein 135

Protein Development Research Biobanking 135

Pharmaceutical Technology

OCTOBER 18, 2022

Last week, Nature magazine published a paper detailing an in-situ study of Parkinson’s disease (PD), showing protein structural changes in cerebrospinal fluid (CSF) between healthy individuals and Parkinson’s patients. In PD clinical research, many biomarkers, such as neurofilament, can be measured within the CSF using a lumbar puncture.

Protein 264

Protein Genetics Gene Clinical Research 264

Pharmaceutical Technology

NOVEMBER 29, 2022

Researchers at City of Hope in the US have developed a new potential therapy to treat glioblastoma multiforme (GBM), a kind of brain cancer. For this approach, the team leveraged an oncolytic herpes simplex virus for releasing chemokines, which are signalling proteins that aid in attracting immune cells to tumours.

Development 130

Development Research Antibody Engineer 130

Pharmaceutical Technology

MARCH 21, 2023

Gilead Sciences has exercised its option to exclusively license the investigational targeted protein degrader development candidate, NX‑0479, from clinical-stage biopharmaceutical company Nurix Therapeutics. GS-6791 is the first development candidate from the previous collaboration between Gilead Sciences and Nurix in 2019.

Protein 130

Protein Licensing Licensing Sales 130

Medical Xpress

NOVEMBER 22, 2024

LMU researchers have discovered how the interplay between a key protein and an endolysosomal ion channel promotes tumor development in skin cancer.

Development 121

Development Scientist Protein Research 121

Pharmaceutical Technology

MAY 11, 2023

Bayer has entered a strategic collaboration agreement with biotechnology company Bicycle Therapeutics to discover, develop, manufacture and commercialise Bicycle’s radioconjugates for a number of oncology targets. Bicycle will receive an upfront payment of $45m and up to $1.7bn as potential development and commercially based milestone fees.

Development 162

Development Manufacturing Protein Clinical Development 162

Camargo

NOVEMBER 29, 2021

The development of biological products (or biologics) represents a major advancement in modern medicine, enabling the treatment of patients with many illnesses where no other therapeutics were previously available. Recombinant therapeutic proteins. Fusion proteins. Gene and cellular therapies. Growth factors. Interferons.

Development 180

Development Protein Production Hormones 180

pharmaphorum

SEPTEMBER 16, 2022

Alphabet subsidiary and precision health company Verily recently announced a breakthrough in its AI drug discovery GPCR research collaboration with Sosei Heptares. The companies hope that in the year to come those data targets will be entered for validation, hit generation, and lead selection. Human-first precision health.

Development 135

Development Research Drugs Clinical Trials 135

Pharmaceutical Technology

MAY 15, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: Oncolytic viral proteins. OVs can be attenuated natural viruses or recombinant viruses.

Protein 130

Protein Gene Genetics Gene Therapy 130

XTalks

MARCH 31, 2023

BMS researchers on the mission will study the crystallization of an assortment of their biologics medicines in microgravity. By growing high quality crystal structures of protein-based therapeutics under microgravity, researchers can gain better insights into their complex structures and stability.

Protein 97

Protein Research Development Manufacturing 97

Pharmaceutical Technology

APRIL 28, 2023

Generate Biomedicines has signed a co-development and commercialisation agreement with the University of Texas MD Anderson Cancer Center to expedite the development of new protein therapeutics for oncology using generative AI. It enables innovative and collaborative research to rapidly bring new treatment options to patients.

Development 130

Development Clinical Trials Clinical Trials Protein 130

Pharmaceutical Technology

OCTOBER 12, 2022

Nimbus Therapeutics and Eli Lilly and Company (Lilly) have signed a research partnership and licence agreement to develop and market new therapies that activate a specific AMPK isoform to treat metabolic diseases. The company will lead the research activities, while Lilly will undertake the global development and marketing activities.

Development 130

Development Protein Engineer Drugs 130

Pharmaceutical Technology

AUGUST 2, 2022

Sosei Heptares , a corporate brand of Sosei Group Corporation, has signed a new drug discovery partnership and option-to-license agreement with AbbVie for discovering, developing and marketing new therapies for neurological ailments. On signing of the deal, AbbVie will make an upfront payment of $40m to Sosei Heptares.

Development 147

Development Licensing Licensing Branding 147

AuroBlog - Aurous Healthcare Clinical Trials blog

NOVEMBER 1, 2023

Scientists have developed a new tool for determining the age of eye cells without sampling regenerative tissue, which could make treatments for eye disease more personalized and better targeted. The team, led by researchers from Stanford University, adapted a technique used for analyzing eye fluid.

Protein 189

Protein Scientist Research Development 189

Pharmaceutical Technology

JULY 1, 2022

Twist's VHH libraries, used for discovering and developing antibodies for use in immuno-oncology, will be licensed by Ildong for three years for research and development works. . The post Twist and Ildong to develop antibodies for immuno-oncology applications appeared first on Pharmaceutical Technology.

Antibody 147

Antibody Development Licensing Licensing 147

Pharmaceutical Technology

JUNE 28, 2022

Researchers at the Rensselaer Polytechnic Institute in the US have received a five-year, $3.5m grant from the National Institutes of Health (NIH) unit National Institute of Allergy and Infectious Diseases (NIAID) for developing a Covid-19 oral antiviral drug. Those drugs that hinder only CLpro did not enhance the effects of remdesivir.

Development 147

Development Bioinformatics Drugs Allergies 147

Pharmaceutical Technology

MAY 19, 2023

ImmunoForge has expanded its licence agreement with Duke University in North Carolina, US, to jointly improve research and drug development opportunities. ImmunoForge chief technology officer Dr Jim Balance pioneered the clinical development of peptide drugs genetically fused to ELPs.

Development 130

Development Drugs Licensing Licensing 130

Pharmaceutical Technology

APRIL 21, 2023

In May 2022, they signed a research partnership and exclusive option licence agreement for the development of antibodies to reduce tumour microenvironment-mediated immunosuppression. The companies signed another research collaboration agreement for multi-target antibody discovery in January 2023.

Antibody 264

Antibody Licensing Licensing Protein 264

Pharmaceutical Technology

SEPTEMBER 14, 2022

API peptides and proteins-based drugs have gained much attention in the past decade. Victoza, Copaxone, Lupron, Zoladex, Sandostatin, and Somatuline are some of the popularly marketed peptide API therapeutic drugs while more than 600 peptide-based pharmacological leads are being investigated worldwide, across various phases of development.

Protein 100

Protein Marketing Manufacturing Reagent 100

Pharmaceutical Technology

OCTOBER 20, 2022

PIC Therapeutics has raised $35m in a Series A funding round led by OrbiMed to develop therapies for drug-resistant breast cancer. The company will utilise the Series A funds to progress its small molecule drug presently in development into first-in-human clinical trials for advanced metastatic breast cancer.

Development 130

Development Drugs Protein Life Science 130

Pharmaceutical Technology

APRIL 5, 2023

Absci has collaborated with bioinformatics firm M2GEN to expedite the development of new cancer medicines. Absci stated that this collaboration combines AI drug creation technology and oncology bioinformatics, thereby reducing the time and cost of cancer drug development.

Development 130

Development Bioinformatics Drugs Immune Response 130

Pharmaceutical Technology

OCTOBER 21, 2022

DJS focuses on the discovery and development of antibody therapies that act on difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs). With the takeover, AbbVie will gain access to the HEPTAD platform, which would complement its existing expertise in biotherapeutics research. .

Antibody 217

Antibody Protein Licensing Licensing 217

Pharmaceutical Technology

JANUARY 16, 2023

Ono Pharmaceutical and Monash University have entered an option and research collaboration for the discovery and development of antibodies that target G protein-coupled receptors (GPCRs). The post Ono Pharmaceutical enters research deal with Monash University appeared first on Pharmaceutical Technology.

Research 130

Research Antibody Sales Development 130

Medical Xpress

MAY 3, 2023

Cartilage is the tissue that protects bones by providing shock absorption and facilitates smooth joint movement. Due to its limited intrinsic healing capacity, stem cell transplantation is a promising therapeutic approach to address cartilage inflammation and damage, as well as to promote cartilage regeneration.

Protein 96

Protein Development Research 96